UBS Group
INBX icon

UBS Group’s Inhibrx INBX Stock Holding History

UBS Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Sell
48,137
-25,562
-35% -$1.9M ﹤0.01% 4513
2025
Q4 		$5.82M Buy
73,699
+64,273
+682% +$4.38M ﹤0.01% 3876
2025
Q3 		$317K Sell
9,426
-36,558
-80% -$900K ﹤0.01% 6401
2025
Q2 		$656K Buy
45,984
+18,516
+67% +$239K ﹤0.01% 5787
2025
Q1 		$384K Buy
27,468
+9,711
+55% +$132K ﹤0.01% 6066
2024
Q4 		$273K Buy
17,757
+11,716
+194% +$178K ﹤0.01% 6257
2024
Q3 		$94.6K Buy
6,041
+2,836
+88% +$39.8K ﹤0.01% 6415
2024
Q2 		$45.4K Buy
+3,205
New +$50.1K ﹤0.01% 6763

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

UBS Group's INBX Position: Q1 2026 in Review

UBS Group reduced its Inhibrx (INBX) stake by 35% in Q1 2026, selling an estimated $1.9M and leaving 48,137 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #4513.

UBS Group first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.82M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • UBS Group held 48,137 shares of Inhibrx worth $3.24M as of Q1 2026.
  • UBS Group sold 25,562 Inhibrx shares in Q1 2026, an estimated $1.9M.
  • Inhibrx made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4513 holding.
  • UBS Group first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • UBS Group's Inhibrx position peaked at $5.82M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.